Abstract Number: 578 • 2016 ACR/ARHP Annual Meeting
Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?
Background/Purpose: Antibodies against cyclic citrullinated peptides (anti-CCP) have been suggested to identify a more severe phenotype of rheumatoid arthritis. In this study we have analysed…Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…Abstract Number: 2707 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against CD74 – a New Diagnostic Marker for Spondyloarthritis (SpA)
Background/Purpose: Spondyloarthritis (SpA) is a common debilitating inflammatory disorder. Pathogenesis of axial SpA (axSpA) including ankylosing spondylitis (AS) is still largely unclear. Diagnosis is difficult,…Abstract Number: 661 • 2016 ACR/ARHP Annual Meeting
Epitope Specificity and End-Organ Susceptibility Dictates Anti-Ro52 Mediated Salivary Gland Dysfunction
Background/Purpose: Circulating autoantibodies reactive against Ro52 are detected in the sera of 70% of patients with Sjögren’s syndrome (SS), and their presence has been associated…Abstract Number: 1781 • 2016 ACR/ARHP Annual Meeting
Analysis of Influences of Various Factors on the Prognosis of Acute Confusional State of Diffuse Psychiatric/Neuropsychological Syndromes in Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE), especially diffuse psychiatric/neuropsychological syndromes (diffuse NPSLE), is one of the most difficult complications of the disease. For the evaluation…Abstract Number: 2808 • 2016 ACR/ARHP Annual Meeting
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…Abstract Number: 669 • 2016 ACR/ARHP Annual Meeting
RNA-Sequencing Reveals Sjogren’s Syndrome Anti-Ro Negative Patients Share Similar Pathways to Multiple Sclerosis Patients
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease characterized by autoantibodies to Ro and/or La proteins and lymphocytic infiltration into exocrine glands. Multiple sclerosis (MS)…Abstract Number: 1834 • 2016 ACR/ARHP Annual Meeting
Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Background/Purpose: The earliest autoantibodies in lupus are directed against the autoantigen Ro60, an RNA binding protein with orthologs that we identified in a subset of…Abstract Number: 2819 • 2016 ACR/ARHP Annual Meeting
Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the presence of autoantibodies. Among the complications of SLE, neuropsychiatric manifestations (NPSLE) can…Abstract Number: 791 • 2016 ACR/ARHP Annual Meeting
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
Background/Purpose: The indirect immunofluorescence (IIF) pattern observed in the antinuclear antibody (ANA) test provides an initial assessment of autoantibody responses in candidate patients who have…Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…Abstract Number: 813 • 2016 ACR/ARHP Annual Meeting
Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling
Background/Purpose: Systemic sclerosis (SSc) is a remarkably heterogeneous autoimmune disease, for which effective disease-modifying therapies are still lacking. The most widely used classification divides SSc…Abstract Number: 1900 • 2016 ACR/ARHP Annual Meeting
Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?
Background/Purpose: Anti-topoisomerase antibodies (ATA) in systemic sclerosis have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However,…Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 28
- Next Page »